MAIA Biotechnology receives USAN Council approval for ‘Ateganosine’ name

MAIA Biotechnology (MAIA) announced that the United States Adopted Names Council has approved “ateganosine” as the nonproprietary name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment for advanced non-small cell lung cancer. Generic drug names are used in product information, drug regulation, labelling and prescribing as for promotional materials and scientific literature. MAIA will retain the name THIO in its clinical trial designations